Retraction: Association of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients (PLoS ONE (2011) 6: 11 (e25933) DOI: 10.1371/journal.pone.0025933);Association of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Yu, Xiaobo ^a   Xie, Haiyang ^a   Wei, Bajin ^a   Zhang, Min ^a   Wang, Weilin ^a   Wu, Jian ^a   Yan, Sheng ^a   Zheng, Shusen ^a   Zhou, Lin ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER; TACROLIMUS; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BODY WEIGHT; CHINESE; CONTROLLED STUDY; DNA EXTRACTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; MDR1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; ASIAN; BLOOD; ETHNIC GROUP; ETHNOLOGY; GENETICS; IMMUNOLOGY; LIVER TRANSPLANTATION; MIDDLE AGED; PHYSIOLOGY;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHNIC GROUPS; FEMALE; HAPLOTYPES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS; YOUNG ADULT;

EID: 81055141167     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0220759     Document Type: Erratum

References (52)

1. Bowman LJ, Brennan DC, (2008) The role of tacrolimus in renal transplantation. Expert Opin Pharmacother 9: 635-643.
2. Thervet E, Anglicheau D, Legendre C, Beaune P, (2008) Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther Drug Monit 30: 143-150.
3. Iwasaki K, (2007) Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 22: 328-335.
4. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM, (2003) P-glycoprotein: from genomics to mechanism. Oncogene 22: 7468-7485.
5. Zhou SF, (2008) Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38: 802-832.
6. Fung KL, Gottesman MM, (2009) A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 1794: 860-871.
7. Dirks NL, Huth B, Yates CR, Meibohm B, (2004) Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther 42: 701-718.
8. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, et al. (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525-528.
9. Cavaco I, Gil JP, Gil-Berglund E, Ribeiro V, (2003) CYP3A4 and MDR1 alleles in a Portuguese population. Clin Chem Lab Med 41: 1345-1350.
10. Chinn LW, Kroetz DL, (2007) ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther 81: 265-269.
11. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97: 3473-3478.
12. Kaya P, Gunduz U, Arpaci F, Ural AU, Guran S, (2005) Identification of polymorphisms on the MDR1 gene among Turkish population and their effects on multidrug resistance in acute leukemia patients. Am J Hematol 80: 26-34.
13. Pechandova K, Buzkova H, Slanar O, Perlik F, (2006) Polymorphisms of the MDR1 gene in the Czech population. Folia Biol (Praha) 52: 184-189.
14. Wang D, Sadee W, (2006) Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). Aaps J 8: E515-520.
15. Clark AG, (2004) The role of haplotypes in candidate gene studies. Genet Epidemiol 27: 321-333.
16. Stram DO, (2004) Tag SNP selection for association studies. Genet Epidemiol 27: 365-374.
17. Lee JE, Choi JH, Lee JH, Lee MG, (2005) Gene SNPs and mutations in clinical genetic testing: haplotype-based testing and analysis. Mutat Res 573: 195-204.
18. Barrett JC, Fry B, Maller J, Daly MJ, (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
19. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
20. Wang J, Zeevi A, McCurry K, Schuetz E, Zheng H, et al. (2006) Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors. Transpl Immunol 15: 235-240.
21. Bandur S, Petrasek J, Hribova P, Novotna E, Brabcova I, et al. (2008) Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. Transplantation 86: 1206-1213.
22. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ, (2003) Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13: 89-95.
23. Chen B, Zhang W, Fang J, Jin Z, Li J, et al. (2009) Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients. Xenobiotica 39: 931-938.
24. Hosohata K, Masuda S, Yonezawa A, Katsura T, Oike F, et al. (2009) MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients. Pharm Res 26: 1590-1595.
25. Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, et al. (2004) CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14: 471-478.
26. Anglicheau D, Le Corre D, Lechaton S, Laurent-Puig P, Kreis H, et al. (2005) Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 5: 595-603.
27. Masuda S, Goto M, Okuda M, Ogura Y, Oike F, et al. (2005) Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients. Transplant Proc 37: 1728-1729.
28. Wei-lin W, Jing J, Shu-sen Z, Li-hua W, Ting-bo L, et al. (2006) Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl 12: 775-780.
29. Loh PT, Lou HX, Zhao Y, Chin YM, Vathsala A, (2008) Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients. Transplant Proc 40: 1690-1695.
30. Wu L, Xu X, Shen J, Xie H, Yu S, et al. (2007) MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation. J Surg Oncol 96: 62-68.
31. Kuzuya T, Kobayashi T, Moriyama N, Nagasaka T, Yokoyama I, et al. (2003) Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. Transplantation 76: 865-868.
32. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, et al. (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3: 477-483.
33. Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, et al. (2004) CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 75: 422-433.
34. Drozdzik M, Mysliwiec K, Lewinska-Chelstowska M, Banach J, Drozdzik A, et al. (2004) P-glycoprotein drug transporter MDR1 gene polymorphism in renal transplant patients with and without gingival overgrowth. J Clin Periodontol 31: 758-763.
35. Kotrych K, Domanski L, Gornik W, Drozdzik M, (2005) MDR1 gene polymorphism in allogeenic kidney transplant patients with tremor. Pharmacol Rep 57: 241-245.
36. Wang W, Zhang XD, Guan DL, Lu YP, Ma LL, et al. (2005) Relationship between MDR1 polymorphism and blood concentration of cyclosporine A. Chin Med J (Engl) 118: 2097-2100.
37. Akbas SH, Bilgen T, Keser I, Tuncer M, Yucetin L, et al. (2006) The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. Transplant Proc 38: 1290-1292.
38. Kotrych K, Sulikowski T, Domanski L, Bialecka M, Drozdzik M, (2007) Polymorphism in the P-glycoprotein drug transporter MDR1 gene in renal transplant patients treated with cyclosporin A in a Polish population. Pharmacol Rep 59: 199-205.
39. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W, (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15: 693-704.
40. Masuda S, Goto M, Fukatsu S, Uesugi M, Ogura Y, et al. (2006) Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clin Pharmacol Ther 79: 90-102.
41. Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, et al. (2008) Relation between mRNA expression level of multidrug resistance 1/ABCB1 in blood cells and required level of tacrolimus in pediatric living-donor liver transplantation. J Pharmacol Exp Ther 325: 610-616.
42. Li D, Gui R, Li J, Huang Z, Nie X, (2006) Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. Transplant Proc 38: 2850-2852.
43. Bonhomme-Faivre L, Devocelle A, Saliba F, Chatled S, Maccario J, et al. (2004) MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. Transplantation 78: 21-25.
44. Hu YF, Qiu W, Liu ZQ, Zhu LJ, Tu JH, et al. (2006) Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clin Exp Pharmacol Physiol 33: 1093-1098.
45. Balram C, Sharma A, Sivathasan C, Lee EJ, (2003) Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br J Clin Pharmacol 56: 78-83.
46. Yates CR, Zhang W, Song P, Li S, Gaber AO, et al. (2003) The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 43: 555-564.
47. Foote CJ, Greer W, Kiberd B, Fraser A, Lawen J, et al. (2007) Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients. Transplantation 83: 1380-1384.
48. Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, et al. (2001) Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11: 175-184.
49. Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, et al. (2003) Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 14: 1889-1896.
50. Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, et al. (2008) Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 18: 413-423.
51. Nebert DW, Zhang G, Vesell ES, (2008) From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev 40: 187-224.
52. Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, et al. (2009) Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 41: 1234-1237.